The largest dataset of randomized controlled trials looking into the safety of ACE inhibitors and angiotensin receptor blockers in patients with COVID-19 demonstrated encouraging results; however, there was a new observation of an association with acute kidney injury in hospitalized patients.

The meta-analysis noted that there was about two times increased risk of acute kidney injury in hospitalized patients with the use of ACE inhibitors and angiotensin receptor blockers in acute COVID-19 (7% vs 3.6%). There was no effect of renin-angiotensin system blockers, in comparison with control, on all-cause mortality (7.2% vs 7.5%, relative risk 0.95), either overall or in subgroups characterized by severity or trial type (RASi initiation or continuation).

The new meta-analysis was presented at the American Heart Association (AHA) Scientific Sessions… (Medscape)